PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsPipecuronium
Pipecuronium
Arduan (pipecuronium) is a small molecule pharmaceutical. Pipecuronium was first approved as Arduan on 1990-06-26.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pipecuronium bromide
Tradename
Company
Number
Date
Products
ARDUANOrganonN-019638 DISCN1990-06-26
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
berinertBiologic Licensing Application2009-11-10
cinryzeBiologic Licensing Application2010-11-01
covaryxunapproved drug other2020-01-25
covaryx covaryxunapproved drug other2013-02-26
eemtunapproved drug other2020-01-22
eemt eemtunapproved drug other2013-03-01
esterified estrogens and methyltestosteroneunapproved drug other2025-02-10
esterified estrogens and methyltestosterone full strength esterified estrogens and methyltestosterone half strengthunapproved drug other2025-03-10
esterified estrogens and methytestesteroneunapproved drug other2022-11-25
estratest f.s.unapproved drug other2024-09-06
Show 18 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
— M03: Muscle relaxants
— M03A: Muscle relaxants, peripherally acting agents
— M03AC: Other quaternary ammonium compounds in atc, muscle relaxants, peripherally acting
— M03AC06: Pipecuronium bromide
HCPCS
No data
Clinical
Clinical Trials
548 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertriglyceridemiaD015228EFO_0004211—33149533
HypercholesterolemiaD006937——1—332532
Cardiovascular diseasesD002318EFO_0000319I985—741329
Healthy volunteers/patients———41—21521
DyslipidemiasD050171——31341021
Type 2 diabetes mellitusD003924EFO_0001360E1121231018
InflammationD007249MP_0001845—1423817
Diabetes mellitusD003920EFO_0000400E08-E131233816
HyperlipidemiasD006949EFO_0003774E78.5—1221116
AtherosclerosisD050197EFO_0003914I25.11—24613
Show 54 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
KetosisD007662—R82.4241—2228
LeukemiaD007938—C957211——23
Myeloid leukemia acuteD015470—C92.04181——20
SyndromeD013577——5153—120
Heart failureD006333EFO_0003144I50434—718
Myelodysplastic syndromesD009190—D464151——17
PreleukemiaD011289——4111——13
ObesityD009765EFO_0001073E66.9121—1013
Wolman diseaseD015223Orphanet_75233E75.5152—511
Non-small-cell lung carcinomaD002289——361——9
Show 77 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223—C85.9514———15
Myeloid leukemiaD007951—C92414———15
NeoplasmsD009369—C80510———13
Breast neoplasmsD001943EFO_0003869C5068——213
RecurrenceD012008——510———13
Non-hodgkin lymphomaD008228—C85.939———10
Hodgkin diseaseD006689—C8129———10
CarcinomaD002277—C80.029———9
Myeloproliferative disordersD009196—D47.119———9
Multiple myelomaD009101—C90.019———9
Show 155 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AgingD000375GO_0007568R41.811———56
VasoconstrictionD014661——3————3
GlioblastomaD005909EFO_0000515—2————2
GliosarcomaD018316——2————2
EczemaD004485—L30.91———12
Pleural diseasesD010995——2————2
Pancreatic ductal carcinomaD021441——1————1
Sickle cell anemiaD000755EFO_0000697D571————1
Beta-thalassemiaD017086Orphanet_848D56.11————1
ThalassemiaD013789EFO_1001996D561————1
Show 15 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OverweightD050177—E66.3————99
HypoxiaD000860—R09.02————77
Parkinson diseaseD010300EFO_0002508G20————44
HepatitisD006505—K75.9————33
Pediatric obesityD063766——————22
Weight lossD015431——————22
MenopauseD008593EFO_0003922N95————22
Glucose intoleranceD018149HP_0000833R73.03————22
Biological availabilityD001682——————22
Wasting syndromeD019282——————22
Show 99 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePipecuronium
INNpipecuronium bromide
Description
Pipecuronium bromide is a steroid ester.
Classification
Small molecule
Drug classquaternary ammonium derivatives: neuromuscular blocking agents; quaternary ammonium derivatives: neuromuscular blocking agents
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H](N3CC[N+](C)(C)CC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CC[N+](C)(C)CC1
Identifiers
PDB—
CAS-ID68399-58-6
RxCUI—
ChEMBL IDCHEMBL1201206
ChEBI ID8230
PubChem CID65332
DrugBank—
UNII IDR6ZTY81RE1 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Cinryze – Shire
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Cinryze – Takeda
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Ruconest – Pharming
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 260,504 documents
View more details
Safety
Black-box Warning
Black-box warning for: Covaryx, Covaryx covaryx, Eemt, Eemt eemt, Esterified estrogens and methyltestosterone, Esterified estrogens and methyltestosterone full strength esterified estrogens and methyltestosterone half strength, Esterified estrogens and methytestesterone, Estratest f.s., Estratest f.s. estratest h.s., Estratest fs estratest hs, Menest, Omega-3 rx complete, Omega-3 well pack
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
23 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use